Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions

Published date: 18 April 2023

Additional Information: Funding Information: We are grateful to the staff of Advanced Photon Source BL 23-IDD for assistance. GM/CA@APS has been funded by the National Cancer Institute ( ACB-12002 ) and the National Institute of General Medical Sciences ( AGM-12006 , P30GM138396 ). This research used resources of the Advanced Photon Sciences under contract no. DE-AC02-06CH11357 . This work is supported by the Netherlands Organisation for Scientific Research (N.W.O.) Vici grant (R.W.S.); Bill & Melinda Gates Foundation , Collaboration for AIDS Vaccine Discovery (C.A.V.D.) grants INV-002022 (R.W.S.) and OPP1115782 / INV-002916 (A.B.W.); Fondation Dormeur, Vaduz (R.W.S.); and grants from the NIAID , Division of AIDS , NIH UM1 grants for the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID; UM1530AI100645 and Consortia for HIV/AIDS Vaccine Development [ CHAVD ]) UM1AI144371 to B.F.H. and R01 grant AI087202 (L.K.V.). P.J.K. and J.P.M. are supported by R01 AI036082 and A.B.W., I.A.W., R.W.S., P.J.K., and J.P.M. are supported by a HIVRAD P01 AI110657 grant. M.C. is funded by the International AIDS Vaccine Initiative (IAVI) through grant INV-008352 and the Bill & Melinda Gates Foundation OPP1153692 . Funding for the neutralization assays was provided by NIH / NIAID contract #HHSN272201800004C . Funding Information: We are grateful to the staff of Advanced Photon Source BL 23-IDD for assistance. GM/CA@APS has been funded by the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006, P30GM138396). This research used resources of the Advanced Photon Sciences under contract no. DE-AC02-06CH11357. This work is supported by the Netherlands Organisation for Scientific Research (N.W.O.) Vici grant (R.W.S.); Bill & Melinda Gates Foundation, Collaboration for AIDS Vaccine Discovery (C.A.V.D.) grants INV-002022 (R.W.S.) and OPP1115782/INV-002916 (A.B.W.); Fondation Dormeur, Vaduz (R.W.S.); and grants from the NIAID, Division of AIDS, NIH UM1 grants for the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID; UM1530AI100645 and Consortia for HIV/AIDS Vaccine Development [CHAVD]) UM1AI144371 to B.F.H. and R01 grant AI087202 (L.K.V.). P.J.K. and J.P.M. are supported by R01 AI036082 and A.B.W. I.A.W. R.W.S. P.J.K. and J.P.M. are supported by a HIVRAD P01 AI110657 grant. M.C. is funded by the International AIDS Vaccine Initiative (IAVI) through grant INV-008352 and the Bill & Melinda Gates Foundation OPP1153692. Funding for the neutralization assays was provided by NIH/NIAID contract #HHSN272201800004C. Conceptualization: M.M.-R. R.D. B.F.H. L.W. L.K.V. and R.W.S.; investigation: T.G.C. M.M.-R. J.Z. A.S. A.S.K. A.L. R.D. J.A. J.L.S. J.C.P. I.d.M.S. A.Y. M.D. Y.A. T.P.L.B. S.V. J.M.B. A.N. C.J. W.-H.L. M.P. J.A.B. M.J.v.B. and P.J.K.; methodology: T.G.C. M.M.-R. J.Z. A.S. S.K. M.P. M.C. P.J.K. I.A.W. K.W. L.K.V. and R.W.S.; project administration: T.G.C. M.M.-R. K.W. L.K.V. and R.W.S.; supervision: C.L. D.M. G.O. A.B.W. M.C. J.P.M. P.J.K. B.F.H. I.A.W. K.W. L.K.V. and R.W.S.; writing – original draft: T.G.C. L.K.V. and R.W.S.; review and editing: all authors. Amsterdam UMC has filed a patent application related to germline-targeting HIV-1 Env trimers. Publisher Copyright: © 2023 The Author(s)

Keywords: HIV antibodies, HIV seropositivity, HIV-1/genetics, animals, antibodies, neutralizing, broadly neutralizing antibodies, mice, vaccination, insertions, mouse model, deletions, vaccines, neutralizing antibodies, bNAbs, germline-targeting, NGS, HIV-1 Env

Local EPrints ID: 477207

URI: http://eprints.soton.ac.uk/id/eprint/477207

DOI: doi:10.1016/j.xcrm.2023.101003

ISSN: 2666-3791

PURE UUID: ec4dee9f-0341-45cd-902c-dd3c8c79cb3c

ORCID for Joel D. Allen: orcid.org/0000-0003-2547-968X

ORCID for Max Crispin: orcid.org/0000-0002-1072-2694

Date deposited: 01 Jun 2023 16:39

Last modified: 12 Jul 2024 02:09